The primary objective ofthe Glioma SPORE Career Development Program (CDP) is to attract talented new investigators to translational glioblastoma research. Potential CDP awardees include junior faculty beginning their careers or established faculty members in other fields who wish to redirect their interests and efforts to glioblastoma research. We will establish a comprehensive, system-wide process for solicitation of CDP applications and an expert-based review process to select the most meritorious applicants. The CDP program faculty will consist of a multidisciplinary cohort of experienced, senior mentors for CDP awardees. The CDP will provide limited-duration funding for promising, junior translational investigators who are focused on glioma research. The program will provide support, mentoring and monitoring for CDP awardees. We will establish a monitoring process to measure progress and outcomes of CDP awardees and the CDP program. We will carefully monitor the progress of awardees through clearly enumerated metrics. The CDP will be assessed on an annual basis by the internal and external advisory boards. The CDP will leverage institutional resources to support and enhance the success of the program.
The Career Development Program will provide research support for junior or new investigators in the field of brain tumor research. Through support, mentoring and monitoring it is anticipated that the program will enable awardees to embark on sucessful careers in brain tumor research that will ultimately benefit patients.
|Taylor, Jennie W; Dietrich, Jorg; Gerstner, Elizabeth R et al. (2015) Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol 121:557-63|
|Schmit, Fabienne; Utermark, Tamara; Zhang, Sen et al. (2014) PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111:6395-400|
|Cheng, Hailing; Liu, Pixu; Zhang, Fan et al. (2014) A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 74:15-23|
|Francis, Joshua M; Zhang, Cheng-Zhong; Maire, Cecile L et al. (2014) EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov 4:956-71|
|Sullivan, James P; Nahed, Brian V; Madden, Marissa W et al. (2014) Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4:1299-309|
|Maire, Cecile L; Ligon, Keith L (2014) Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol 16 Suppl 8:viii1-6|
|Wakimoto, Hiroaki; Tanaka, Shota; Curry, William T et al. (2014) Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 20:2898-909|